XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. | ClinicalTrials HQ

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
The Safety, Tolerability, and Efficacy of Dopaminergic Neural Progenitor Cells (XS411CN Cell Injection) for the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P).	the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P)	Not yet recruiting	Phase 1	2026-06-01		NCT07617012
Clinical Study to Evaluate XS411 in Treatment of Early-onset Parkinson's Disease	Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy	Recruiting	Phase 1 / Phase 2	2025-12-29		NCT07166757
Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial	central nervous system disorder, injury, nervous system disorder, nervous system injury, spinal cord disorder, spinal cord injury	Recruiting	Phase 1	2025-11-25		NCT06976229
Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase II Randomized Controlled Trial	central nervous system disorder, injury, nervous system disorder, nervous system injury, spinal cord disorder, spinal cord injury	Not yet recruiting	Phase 2	2025-11-25		NCT06974968
The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis	Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder	Recruiting	Phase 1	2025-11-21		NCT07118319